AmacaThera, a leader in the development of novel injectable, localized therapeutics based upon its AmacaGel delivery platform, announced the closing of a CAD$4.0 million financing round. The proceeds will be used to accelerate the clinical development of the AMT-143 formulation, with the objective of it being a best-in-class, non-opioid, therapeutic able to provide an extended period of post-surgical pain relief and reduce with the aim of eliminating the need for opioids in the postsurgical recovery period.
AmacaThera is an OBIO® member, an alumnus of all OBIO® programs and presented at the OBIO® Investment Summit.